Korean J Med > Volume 96(2); 2021 > Article |
|
Saxagliptin (SAVOR-TIMI 53) | Alogliptin (EXAMINE) | Sitagliptin (TECOS) | Linagliptin (CARMELINA) | |
---|---|---|---|---|
Main inclusion criteria | Type 2 diabetes, History of or multiple risk factors for CVD | Type 2 diabetes, ACS within 15–90 days before randomization | Type 2 diabetes, Preexisting CVD | Type 2 diabetes, High CV and renal risk |
Primary outcome (3-point MACE)a | HR 1.00 (0.89–1.12) | HR 0.96 (95% UL ≤1.16) | HR 0.98 (0.89–1.08) | HR 1.02 (0.89–1.17) |
CV death | HR 1.03 (0.87–1.22) | HR 0.85 (0.66–1.10) | HR 1.03 (0.89–1.19) | HR 0.96 (0.81–1.14) |
Non-fatal MI | HR 0.95 (0.80–1.12) | HR 1.08 (0.88–1.33) | HR 0.95 (0.81–1.11) | HR 1.12 (0.90–1.40) |
Non-fatal stroke | HR 1.11 (0.88–1.39) | HR 0.91 (0.55–1.50) | HR 0.97 (0.79–1.19) | HR 0.91 (0.67–1.23) |
HF hospitalization | HR 1.27 (1.07–1.51) | HR 1.07 (0.79–1.46) | HR 1.00 (0.83–1.20) | HR 0.90 (0.74–1.08) |
Unstable angina | HR 1.19 (0.89–1.60) | HR 0.90 (0.60–1.37) | HR 0.90 (0.70–1.16) | HR 0.87 (0.57–1.31) |
All-cause mortality | HR 1.11 (0.96–1.27) | HR 0.80 (0.62–1.03) | HR 1.01 (0.90–1.14) | HR 0.98 (0.84–1.13) |
Liraglutide (LEADER) | Albiglutide (Harmony Outcomes) | Semaglutide (SUSTAIN-6) | Dulaglutide (REWIND) | Lixisenatide (ELIXA) | Exenatide (EXSCEL) | |
---|---|---|---|---|---|---|
Main inclusion criteria | Type 2 diabetes, Preexisting CVD, CKD, or HF at ≥ 50 years of age or CV risk at ≥ 60 years of age | Type 2 diabetes, Preexisting CVD | Type 2 diabetes, Preexisting CVD, HF, or CKD at ≥ 50 years of age or CV risk at ≥ 60 years of age | Type 2 diabetes, Prior ASCVD event or risk factors for ASCVD | Type 2 diabetes, History of ACS (< 180 days) | Type 2 diabetes with or without preexisting CVD |
Primary out- come (3-point MACE)a | HR 0.87 (0.78–0.97) | HR 0.78 (0.68–0.90) | HR 0.74 (0.58–0.95) | HR 0.88 (0.79–0.99) | HR 1.02 (0.89–1.17) | HR 0.91 (0.83–1.00) |
CV death | HR 0.78 (0.66–0.93) | HR 0.93 (0.73–1.19) | HR 0.98 (0.65–1.48) | HR 0.91 (0.78–1.06) | HR 0.98 (0.78–1.22) | HR 0.88 (0.76–1.02) |
Non-fatal MI | HR 0.86 (0.73–1.00) | HR 0.75 (0.61–0.90) | HR 0.74 (0.51–1.08) | HR 0.96 (0.79–1.15) | HR 1.03 (0.87–1.22) | HR 0.97 (0.85–1.10) |
Non-fatal stroke | HR 0.86 (0.71–1.06) | HR 0.86 (0.66–1.14) | HR 0.61 (0.38–0.99) | HR 0.76 (0.61–0.95) | HR 1.12 (0.79–1.58) | HR 0.85 (0.70–1.03) |
HF hospitalization | HR 0.87 (0.73–1.05) | - | HR 1.11 (0.77–1.61) | HR 0.93 (0.77–1.12) | HR 0.96 (0.78–1.23) | HR 0.94 (0.78–1.13) |
Unstable angina | HR 0.98 (0.76–1.26) | - | HR 0.82 (0.47–1.44) | HR 1.14 (0.84–1.54) | HR 1.11 (0.47–2.62) | HR 1.05 (0.94–1.18) |
All-cause mortality | HR 0.85 (0.74–0.97) | HR 0.95 (0.79–1.16) | HR 1.05 (0.74–1.50) | HR 0.90 (0.80–1.01) | HR 0.94 (0.78–1.13) | HR 0.86 (0.77–0.97) |
Outcomes reported as adjusted hazard ratios (HRs) with 95% confidence interval.
-, not assessed/reported; CVD, cardiovascular disease; CKD, chronic kidney disease; HF, Heart failure; CV, cardiovascular; ASCVD, atherosclerotic cardiovascular disease; MI, myocardial infarction.
a Primary outcome was a composite of 3-point MACE (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) in all trials except Harmony Outcomes and ELIXA, in which primary outcome was a composite of 4-point MACE (death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or unstable angina).